Corbus Pharmaceuticals Holdings, Inc. Increase (Decrease) in Deferred Revenue
Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported Increase (Decrease) in Deferred Revenue of -$4.73 million for the 6-month period ending 2020-06-30, per its 10-Q filed 2021-08-12.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2021-08-12
- Corbus Pharmaceuticals Holdings, Inc. increase (decrease) in deferred revenue for the quarter ending 2019-12-31 was $107.55K.
- Corbus Pharmaceuticals Holdings, Inc. increase (decrease) in deferred revenue for the quarter ending 2019-09-30 was -$2.59M.
- Corbus Pharmaceuticals Holdings, Inc. increase (decrease) in deferred revenue for the quarter ending 2019-06-30 was -$29.52M.
- Corbus Pharmaceuticals Holdings, Inc. increase (decrease) in deferred revenue for the quarter ending 2019-03-31 was $25.54M.
- Corbus Pharmaceuticals Holdings, Inc. increase (decrease) in deferred revenue for fiscal 2019 was -$6.46M.
- Corbus Pharmaceuticals Holdings, Inc. increase (decrease) in deferred revenue for fiscal 2018 was -$4.79M.
- Corbus Pharmaceuticals Holdings, Inc. increase (decrease) in deferred revenue for fiscal 2017 was -$1.94M, a 2290.40% decline from fiscal 2016.
- Corbus Pharmaceuticals Holdings, Inc. increase (decrease) in deferred revenue for fiscal 2016 was $88.58K, a 95.22% decline from fiscal 2015.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 9 month as first filed | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|---|
| 2020-06-30 | -$4.73M 10-Q · filed 2021-08-12 | ||||
| 2019-12-31 | $107.55K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | -$2.48M derived: sum of 2 quarters · filed 2021-03-15 | -$32.00M derived: sum of 3 quarters · filed 2021-03-15 | -$6.46M 10-K · filed 2021-03-15 | |
| 2019-09-30 | -$2.59M derived: 10-Q 9 month − 10-Q/A 6 month · filed 2020-11-09 | -$32.11M derived: sum of 2 quarters · filed 2020-11-09 | -$6.57M 10-Q · filed 2020-11-09 | -$6.46M 10-Q · filed 2019-11-07 | -$8.50M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | -$29.52M derived: 10-Q/A 6 month − 10-Q 3 month · filed 2020-08-31 | -$3.98M 10-Q/A · filed 2020-08-31 | -$5.91M derived: sum of 3 quarters · filed 2020-08-31 | -$7.00M derived: sum of 4 quarters · filed 2020-08-31 | |
| 2019-03-31 | $25.54M 10-Q · filed 2020-05-11 | $23.61M derived: sum of 2 quarters · filed 2020-05-11 | $22.52M derived: sum of 3 quarters · filed 2020-05-11 | ||
| 2018-12-31 | -$1.93M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | -$3.02M derived: sum of 2 quarters · filed 2020-03-16 | -$4.79M 10-K · filed 2020-03-16 | ||
| 2018-09-30 | -$1.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | -$2.86M 10-Q · filed 2019-11-07 | |||
| 2018-06-30 | -$1.77M 10-Q · filed 2018-08-08 | ||||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | -$296.31K derived: sum of 2 quarters · filed 2018-11-08 | -$646.50K derived: sum of 3 quarters · filed 2018-11-08 | -$1.94M 10-K · filed 2018-03-12 | |
| 2017-09-30 | -$296.31K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | -$646.50K derived: sum of 2 quarters · filed 2018-11-08 | -$1.94M 10-Q · filed 2018-11-08 | -$1.32M derived: sum of 4 quarters · filed 2018-11-08 | |
| 2017-06-30 | -$350.19K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | -$1.64M 10-Q · filed 2018-08-08 | -$1.02M derived: sum of 3 quarters · filed 2018-08-08 | -$762.11K derived: sum of 4 quarters · filed 2018-08-08 | |
| 2017-03-31 | -$1.29M 10-Q · filed 2018-05-10 | -$669.37K derived: sum of 2 quarters · filed 2018-05-10 | -$411.92K derived: sum of 3 quarters · filed 2018-05-10 | -$808.52K derived: sum of 4 quarters · filed 2018-05-10 | |
| 2016-12-31 | $624.33K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $881.77K derived: sum of 2 quarters · filed 2018-03-12 | $485.18K derived: sum of 3 quarters · filed 2018-03-12 | $88.58K 10-K · filed 2018-03-12 | |
| 2016-09-30 | $257.44K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$139.16K derived: sum of 2 quarters · filed 2017-11-08 | -$535.75K 10-Q · filed 2017-11-08 | $1.10M derived: sum of 4 quarters · filed 2018-03-12 | |
| 2016-06-30 | -$396.60K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | -$793.20K 10-Q · filed 2017-08-09 | $841.79K derived: sum of 3 quarters · filed 2018-03-12 | -$77.94K derived: sum of 4 quarters · filed 2018-03-12 | |
| 2016-03-31 | -$396.60K 10-Q · filed 2017-05-09 | $1.24M derived: sum of 2 quarters · filed 2018-03-12 | $318.66K derived: sum of 3 quarters · filed 2018-03-12 | ||
| 2015-12-31 | $1.63M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $715.25K derived: sum of 2 quarters · filed 2018-03-12 | $1.85M 10-K · filed 2018-03-12 | ||
| 2015-09-30 | -$919.73K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | $216.63K 10-Q · filed 2016-11-10 | $965.91K 10-Q · filed 2015-11-10 | ||
| 2015-06-30 | $1.14M 10-Q · filed 2016-08-12 | ||||
| 2014-09-30 | $0.00 10-Q · filed 2015-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |